CNBC   |  July 24, 2014

Results hurt by patent expirations: Eli Lilly CEO

John Lechleiter, Eli Lilly CEO, breaks down the pharmaceutical giant's quarterly results. And Lechleiter weighs in on the benefits of investing in R&D.

Share This:

Sorry, we do not have a transcript available for this video at this time.